Cell line · CVCL_1324
Karpas-299
Cancer cell line, Homo sapiens. Anaplastic large cell lymphoma, ALK-positive. 32 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Karpas-299. Cell lines, record CVCL_1324. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1324
On this page
Cell line
As Cellosaurus gives it.
- Name
- Karpas-299
- Accession
- CVCL_1324
- RRID
- RRID:CVCL_1324
- Synonyms
- KARPAS-299, Karpas 299, KARPAS 299, Karpas299, KARPAS299, K299
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 25Y
- Category
- Cancer cell line
- Diseases
- Anaplastic large cell lymphoma, ALK-positive (NCIt C37193); ALK-positive anaplastic large cell lymphoma (ORDO Orphanet_300895)
- Derived from
- Peripheral blood (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers32
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidates. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. | Cell Rep Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed |
1 to 10 of 32
See all 32 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | Karpas-299-CR06 | CVCL_V404 |
Source Cell lines
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| DSMZ | ACC-31 | Discontinued | Cellosaurus |
| ECACC | 06072604 | ECACC | |
| Ximbio | 152418 | Ximbio |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1324
GET https://conductscience.org/api/cell-lines/v1/CVCL_1324/papers?page=2